Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says
This article was originally published in The Pink Sheet Daily
The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.
You may also be interested in...
An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.